May 14, 2018 – Is state-level medical cannabis access mitigating or fueling America’s opioid crisis? Testifying before Congress last week, Drug Enforcement Agency (DEA) acting administrator Robert Patterson claimed the latter. But when he prompted to provide evidence in support of the agency’s position, he acknowledged that he could not. His failure to substantiate this claim is unsurprising. That is because numerous peer-reviewed studies show that increased cannabis access is associated with declining rates of opioid use, abuse, hospitalizations, and mortality. Among patients enrolled in state-sanctioned medical marijuana access programs, participants’ use of not only opioids, but also their use of numerous other prescription medications — such as anti-depressants and anti-anxiety drugs — declines significantly.
ALWAYS WITH YOU – Nov. 2, 2024 - Archaeologists have uncovered a previously unknown effect…
TURN OFF CNN – Nov. 7, 2024 - At Toshikazu Kawaguchi’s book signings, it’s not…
86ed AGAIN? – NOV. 4, 2024 - Two previous rounds of employee cuts in September…
BY A NOSE – Nov. 5, 2024 - Thoroughbred owner and recovering alcoholic Gino Roncelli…
VIDEO – NO VALUE AT ALL – Nov. 4, 2024 - It all started innocently…
WHAT WOULD? – Nov. 4, 2024 - Stephan Lindner, Ph.D., is lead author on a…